ArticleCancer medicine2025
The Epidemiology of Neuroendocrine Carcinomas in Taiwan: A Population-Based Cancer Registry Study.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Epidemiology of Neuroendocrine Carcinomas in Taiwan: A Population-Based Cancer Registry Study.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLung and small cell neuroendocrine carcinomas (SCCs) are the most common sites and histological types of high-grade neuroendocrine carcinoma (NEC). Comprehensive epidemiological information on NECs is limited. We used the Taiwan Cancer Registry database to analyze the nationwide epidemiology and clinical outcomes of NECs in Taiwan.
methodsWe used morphology codes from the International Classification of Diseases for Oncology, third edition (ICD-O-3) and ICD codes to identify the histologic type and sites of NECs, respectively. The Kaplan-Meier method was used to estimate the overall survival (OS) of NECs. The risk of NEC death was evaluated using Cox proportional hazards regression analysis.
resultsThe incidence of NECs in Taiwan was 3.892 per 100,000 in 2006 and increased to 4.039 per 100,000 in 2021, with the predominant site being the lung and bronchus and the histologic type of SCC. The median OS of all NECs was 8.3 months. Female sex, earlier stage, and later diagnosis (2016-2021) were good prognostic factors for the OS of NECs, whereas the histologic type of SCC and large cell neuroendocrine carcinoma, primary sites of the lung and bronchus, esophagus, and unknown primary sites were poor prognostic factors for the OS of NECs. Surgery combined with chemotherapy and/or radiation therapy resulted in longer survival for stage III/IV NECs.
conclusionsDifferences in the incidence trends and clinical outcomes of NECs suggest different etiologies and heterogeneities of NECs. Further investigations on risk factor identification and novel treatment strategies for NECs are warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.